Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 1/20 | 0.64 |
| ▸ | KDR | P35968 | 1/20 | 0.58 |
| ▸ | PPARG | P37231 | 15/20 | 0.58 |
| ▸ | PPARA | Q07869 | 15/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.51 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5202665 | 0.95 | FFAR1 (0.61) | FFAR1KDRPPARGPPARAKDM4E | |
| SCHEMBL4035001 | 0.94 | FFAR1 (0.62) | FFAR1KDRPPARGPPARAKDM4E | |
| SCHEMBL4034488 | 0.94 | FFAR1 (0.62) | FFAR1KDRPPARGPPARAKDM4E | |
| SCHEMBL4030062 | 0.94 | FFAR1 (0.63) | FFAR1KDRPPARGPPARAKDM4E | |
| SCHEMBL4032405 | 0.94 | FFAR1 (0.63) | FFAR1KDRPPARGPPARAKDM4E | |
| SCHEMBL2534811 | 0.94 | FFAR1 (0.63) | FFAR1KDRPPARGPPARAKDM4E | |
| SCHEMBL4032841 | 0.92 | FFAR1 (0.61) | FFAR1KDRPPARGPPARAKDM4E | |
| SCHEMBL4032055 | 0.92 | FFAR1 (0.61) | FFAR1KDRPPARGPPARAKDM4E | |
| SCHEMBL4034630 | 0.91 | FFAR1 (0.68) | FFAR1KDRPPARGPPARAKDM4E | |
| SCHEMBL4037966 | 0.91 | FFAR1 (0.63) | FFAR1KDRPPARGPPARAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1357115-B1 | ALKANOIC ACID DERIVATIVES, PROCESS FOR THEIR PRODUCTION AND USE THEREOF | TAKEDA PHARMACEUTICAL (JP) | 2009-06-17 | — | — | EP | disclosed |
| US-7238716-B2 | Alkanoic acid derivatives process for their production and use thereof | TAKEDA PHARMACEUTICALS COMPANY LIMITED (JP) | 2007-07-03 | — | — | US | disclosed |
| US-20040058965-A1 | Alkanoic acid derivatives process for their production and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-03-25 | — | — | US | disclosed |
| EP-1357115-A1 | ALKANOIC ACID DERIVATIVES, PROCESS FOR THEIR PRODUCTION AND USE THEREOF | Takeda Chemical Industries, Ltd. (JP) | 2003-10-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040058965-A1 | Alkanoic acid derivatives process for their production and use thereof | GPR119, ACOX1, ALK | FFAR1 4/4885KDR 1328/4885PPARG 593/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.